HI
ACRS icon

Harbour Investments’s Aclaris Therapeutics ACRS Stock Holding History

Harbour Investments’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,000
Closed -$15.8K – 2997
2022
Q4 		$15.8K Hold
1,000
– – ﹤0.01% 1765
2022
Q3 		$14K Hold
1,000
– – ﹤0.01% 1782
2022
Q2 		$14K Buy
+1,000
New +$14K ﹤0.01% 1782
2021
Q4 		$15K Buy
1,000
+900
+900% +$13.6K ﹤0.01% 1764
2021
Q3 		$2K Hold
100
– – ﹤0.01% 3263
2021
Q2 		$2K Hold
100
– – ﹤0.01% 3327
2021
Q1 		$3K Buy
+100
New +$1.96K ﹤0.01% 3053

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Harbour Investments's ACRS Position: Q1 2023 in Review

Harbour Investments sold out of Aclaris Therapeutics (ACRS) in Q1 2023, closing a stake of 1,000 shares — an estimated $15.8K sold.

Harbour Investments first reported a position in ACRS in Q1 2021 and held it in 7 quarters. The position peaked at $15.8K in Q4 2022. 148 funds tracked by Wall St. Rank hold ACRS as of Q1 2023.

  • Harbour Investments reported no remaining Aclaris Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Harbour Investments sold 1,000 Aclaris Therapeutics shares in Q1 2023, an estimated $15.8K.
  • Harbour Investments first reported a position in Aclaris Therapeutics in Q1 2021 and held it in 7 quarters.
  • Harbour Investments's Aclaris Therapeutics position peaked at $15.8K in Q4 2022.
  • 148 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2023.

Based on Harbour Investments's 13F filing for Q1 2023, filed 15 May 2023.